Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.
1. A method of treating or reducing the likelihood of development of graft versus host disease (GVHD) in a subject receiving a transplant, comprising administering to the subject a probiotic composition comprising an isolated, human-derived population of anti-inflammatory bacterial cells, wherein said population comprises 3 or more strains of anti-inflammatory bacteria capable of increasing secretion of Interleukin 10 (IL-10) by human peripheral blood mononuclear cells (PBMCs) in vitro, and wherein the population of anti-inflammatory bacterial cells increases IL-10 secretion by human PBMCs by at least 80% or more relative to each strain individually, such that GVHD is treated or the likelihood that the subject develops GVHD is reduced.
2. The method of claim 1 , wherein the anti-inflammatory bacteria decrease secretion of a pro-inflammatory cytokine by human PBMCs.
3. The method of claim 2 , wherein the anti-inflammatory bacteria decrease secretion of a pro-inflammatory cytokine selected from the group consisting of IFNγ, IL-12p70, IL-1α, IL-6, IL-8, MCP1, MIP1α, MIP1β, TNFα, and combinations thereof.
4. The method of claim 1 , wherein the anti-inflammatory bacteria increase secretion of one or more anti-inflammatory cytokines selected from the group consisting of IL-13, IL-4, IL-5, and TGFβ by human PBMCs.
5. The method of claim 1 , wherein the anti-inflammatory bacteria reduce intestinal permeability in the subject.
6. The method of claim 1 , wherein the anti-inflammatory bacteria produce short chain fatty acids.
7. The method of claim 6 , wherein the anti-inflammatory bacteria produce a short chain fatty acid selected from the group consisting of butyrate, acetate, propionate, valerate, and combinations thereof.
8. The method of claim 1 , wherein the anti-inflammatory bacteria are capable of modulating the proportion of one or more cell types selected from the group consisting of Treg cells, Th17 cells, Th1 cells, Th2 cells, and combinations thereof, in the subject.
9. The method of claim 1 , wherein the subject is receiving a bone marrow transplant.
10. The method of claim 1 , wherein the subject is receiving a hematopoietic stem cell transplant.
11. The method of claim 1 , wherein the subject is receiving a solid organ transplant.
12. The method of claim 11 , wherein the solid organ transplant is selected from the group consisting of a kidney transplant, a heart transplant, a lung transplant, a skin transplant, a liver transplant, a pancreas transplant, an intestinal transplant, an endocrine gland transplant, a bladder transplant, and a skeletal muscle transplant.
13. The method of claim 1 , wherein the subject has a disorder selected from the group consisting of a hematopoietic neoplastic disorder, leukemia, lymphoma, and multiple myeloma.
14. The method of claim 1 , wherein the subject has an autoimmune disorder.
15. The method of claim 14 , wherein the autoimmune disorder is selected from the group consisting of lupus, multiple sclerosis, systemic sclerosis, Crohn's disease, type I diabetes, and juvenile idiopathic arthritis.
16. The method of claim 1 , further comprising administering to the subject a prebiotic that enhances the activity of the population of anti-inflammatory bacterial cells.
17. The method of claim 16 , wherein the prebiotic is xylose.
18. The method of claim 1 , wherein the population of anti-inflammatory bacteria cells contains no more than 20 bacterial species.
19. The method of claim 1 , wherein the population of anti-inflammatory bacterial cells contains bacterial species of the genus Blautia, Eubacterium , or Ruminococcus.
20. The method of claim 1 , wherein the probiotic composition is administered to the subject prior to receiving the transplant.
21. The method of claim 1 , wherein the probiotic composition is administered to the subject after receiving the transplant.
22. The method of claim 1 , wherein the probiotic composition is administered to the subject concurrently with the transplant.
23. The method of claim 1 , wherein the subject has not received antibiotics within one month prior to administration of the probiotic composition.
24. The method of claim 1 , wherein the subject has not received vancomycin within one month prior to administration of the probiotic composition.
25. The method of claim 1 , wherein the population of anti-inflammatory bacterial cells comprises Blautia producta.
26. The method of claim 1 , wherein the population of anti-inflammatory bacterial cells comprises Ruminococcus torques.
27. The method of claim 1 , wherein the population of anti-inflammatory bacterial cells comprises Eubacterium ventriosum.
28. The method of claim 1 , wherein the population of anti-inflammatory bacterial cells comprises Blautia producta and Ruminococcus torques.
29. The method of claim 28 , wherein the population of anti-inflammatory bacterial cells comprises Blautia producta, Ruminococcus torques , and one or more bacterial strains selected from the group consisting of Eubacterium rectale, Ruminococcus obeum , and Eubacterium ventriosum.